Multiple-Dose Pharmacokinetics and Pharmacodynamics of Adinazolam in Elderly Subjects
- 1 January 1989
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 06 (5) , 379-386
- https://doi.org/10.1023/a:1015975214070
Abstract
The pharmacokinetics and pharmacodynamics of adinazolam (AD) were evaluated in 21 elderly subjects (mean age, 69 ± 4 years) at four dose levels during a placebo-controlled, double-blind, dose escalation regimen in which the oral dose was varied from 10 to 60 mg daily, in divided doses. Fifteen subjects received adinazolam mesylate; six received placebo. Plasma samples collected during a single dosing interval in each dosing period (3 days) were assayed for adinazolam and monodesmethyl adinazolam (NDMAD) by high-performance liquid chromatography (HPLC). Urine samples were collected during a single interval during the 20- and 40-mg daily dose periods and assayed for NDMAD by HPLC. Pharmacologic effects of adinazolam were assessed using psychomotor performance tests and sedation ratings. Adinazolam pharmacokinetics were linear over the dosage range studied. Daily dose had no significant effect on dose-normalized AUC and Cmax for AD. Dose-normalized NDMAD AUC values as well as β values were not significantly affected by the daily dose of adinazolam. The ratio NDMAD/AD was not substantially affected by the dose. Renal clearance of NDMAD for the 20-and 40-mg daily doses were 5.6 ± 2.1 and 5.5 ± 2.2 liters/hr, respectively, and did not correlate with creatinine clearance. Adinazolam and NDMAD did not substantially accumulate in elderly subjects, even upon multiple dosing at 8-hr intervals. The dosing regimens in this experiment appeared to be well tolerated in the elderly, as performance tests and sedation scores indicated no substantial dose-related effects of adinazolam on psychomotor performance.This publication has 15 references indexed in Scilit:
- Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effectsPsychopharmacology, 1987
- Single dose and steady-state pharmacokinetics of adinazolam after oral administration to manBiopharmaceutics & Drug Disposition, 1987
- ADINAZOLAM - A NEW ANTIDEPRESSANT - FINDINGS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY IN OUTPATIENTS WITH MAJOR DEPRESSION1987
- Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorderPsychopharmacology, 1986
- Temporal Variation in Triazolam Pharmacokinetics and Pharmacodynamics After Oral AdministrationThe Journal of Clinical Pharmacology, 1986
- Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administrationPsychopharmacology, 1984
- Assay of Adinazolam in Plasma by Liquid ChromatographyJournal of Pharmaceutical Sciences, 1984
- Determination of biological activity of adinazolam and its metabolitesJournal of Pharmacy and Pharmacology, 1984
- Daytime Alertness, Insomnia, and BenzodiazepinesSleep, 1982
- Biotransformation of Drugs during AgingGerontology, 1982